LARVOL

ESMO 2024 Quick Takes with LARVOL: Guru Sonpavde, MD In this post-ESMO 2024 Quick Take, Dr. Guru Sonpavde, MD, shares his insights on the practice-changing NIAGARA trial. This randomized phase 3 study, involving approximately 1,000 patients, evaluated neoadjuvant gemcitabine, cisplatin, with or without durvalumab for muscle-invasive bladder cancer. The results showed significant improvements in both event-free survival (hazard ratio: 0.68) and overall survival (hazard ratio: 0.75), signaling a major shift in treatment approaches. Stay tuned for more post-ESMO reflections and updates on how this trial may shape future clinical practice. #ESMO24 #CancerResearch #NIAGARATrial #LARVOLQuickTake

ESMO 2024 Quick Takes with LARVOL : Guru Sonpavde, MD Wrapping up our ESMO 2024 coverage, Dr. Sonpavde provides key insights from the AMBASSADOR trial. This randomized phase 3 study explored adjuvant pembrolizumab in high-risk muscle-invasive urothelial carcinoma, demonstrating a nearly doubled median disease-free survival (DFS) — from 14 months to 29 months. With these promising results, could pembrolizumab follow nivolumab’s path to approval in this setting? Stay tuned for more post-ESMO insights and what these findings could mean for future treatments! #ESMO24 #CancerResearch #AMBASSADORTrial #LARVOLQuickTake

At ESMO - European Society for Medical Oncology 2024, leading oncologists on X have been sharing their reactions to the most impactful clinical trials presented this year. From groundbreaking immunotherapies to advances in precision medicine, their insights are shaping the conversation on the future of oncology treatment. 🩺💡 Follow the discussion and explore detailed updates through LARVOL CLIN: https://bit.ly/47krWpH. #ESMO2024 #Oncology #CancerResearch #ClinicalTrials #MedTwitter #LARVOL #CancerData Connect with the top oncologists here: Philippe Aftimos MD | Toni Choueiri | Yüksel ÜRÜN | Elvina Almuradova | José Fernando Prado Moura | Rohit Gosain, MD | Rahul Gosain, MD, MBA | Paolo Tarantino | Amol Akhade

With ESMO - European Society for Medical Oncology 2024 coming to a close, we’ve curated a list of top oncologists and thought leaders on X (formerly Twitter) who have been sharing their insights throughout the event. From updates on cutting-edge therapies to discussions on key trials, these influencers have been at the forefront of the conversation. Get more detailed insights from LARVOL CLIN here 🔗 https://bit.ly/47krWpH. #ESMO24 #Oncology #OncologyLeaders #CancerResearch #ClinicalTrials #LARVOL #CancerData #PharmaInnovation Here are the top oncologists: Amol Akhade | Yüksel ÜRÜN | Rohit Gosain, MD | Rahul Gosain, MD, MBA | Toni Choueiri | Stephen Liu | Dr Riyaz Shah | Paolo Tarantino | José Fernando Prado Moura | Prof. Dr. Arndt Vogel

As ESMO - European Society for Medical Oncology 2024 concludes, we’re highlighting the top companies that made a mark in oncology. From innovative treatments to impactful clinical trials, these leaders have been pivotal in advancing cancer research and therapies. For more detailed insights, check out LARVOL CLIN here 🔗 https://bit.ly/47krWpH. #ESMO24 #Oncology #ClinicalTrials #CancerResearch #LARVOL #CancerData

The biggest highlights from ESMO - European Society for Medical Oncology 2024 are in! 💡 Groundbreaking immunotherapy advancements 💡 Encouraging data on targeted therapies 💡 Promising results from new clinical trials Stay ahead with detailed insights from the top trials by visiting LARVOL CLIN here: https://bit.ly/47krWpH. #Oncology #ESMO24 #CancerResearch #ClinicalTrials #LARVOL

Mark your calendars! 📅 Team LARVOL will be at Pharma CI Conference USA in Newark, NJ from Sep 25-26! Our CEO, Bruno Larvol, is ready to share insights on AI in Pharma during his talk on Sep 26. We can’t wait to meet up with everyone and have some great conversations! 🎙️💬 See you there! 👋 #PharmaCI #AI #AIinPharma #CompetitiveIntelligence #Oncology #CancerResearch #CancerData #LARVOL

We’re thrilled to share that LARVOL will be featured on New Frontiers in January 2025! 🌟   🎥 In this episode, we’ll dive into how our Oncology Data Intelligence helps pharmaceutical and biotech companies make informed decisions that drive innovation. From clinical trial data to key opinion leader insights, we’re excited to show how our work is making a difference. 🙌   We’d love for you to tune in and watch! 🤩   🔗 Full press release: https://bit.ly/4d9qkAf 🎬 Watch the preview here: https://bit.ly/3ZrAsB6   Can’t wait to share more soon!   #LARVOL #NewFrontiersTV #Oncology #OncologyData #CancerResearch #CancerData #ComingJanuary2025 #TuneIn #DataInnovation #PressRelease #PlanetTVStudios

Team LARVOL had an incredible time at ESMO - European Society for Medical Oncology 2024 in beautiful Barcelona! 🇪🇸✨ We loved connecting with so many of you and sharing insights. Already looking forward to next year – see you in 2025! 🙌 #ESMO24 #Oncology #CancerResearch #CancerData #Networking #LARVOL

Claudine Lamoureux Véronique Crolard Jocelyn RICHARD #ESMO24